WRBY · Earnings event · Q2 2026 · archived
Warby Parker (WRBY) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $0.15 vs estimate $0.11 (+30.0%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $0.11 | $0.15 | +30.0% |
| Revenue (2026-06-30) | — | $235.5M | — |
Revenue source: xbrl.
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated WRBY Sell at 4.5/10. After the Q2 2026 report, the verdict moved to Hold at 4.5/10.
Healthcare context
WRBY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $3.20B
- P/E (fwd)
- 42.5
- P/E (ttm)
- 431.8
- 52-week range
- $14.96–$31.00
- Off 52-week high
- 16.4%
- RSI (14)
- 55
- Volume vs avg
- 0.98×
- Engine score
- 5.2/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.